Neurizon Therapeutics Ratios and Metrics

Market cap in millions AUD. Fiscal year is July - June.

Millions AUD. Fiscal year is Jul - Jun.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 30, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Market Capitalization	53	79	87	26	22	29
Market Cap Growth	-6.19%	-9.23%	232.99%	17.48%	-23.03%	-38.43%
Enterprise Value	47	69	81	25	21	27
Last Close Price	0.07	0.16	0.19	0.07	0.07	0.09
PS Ratio	8.88	51.22	103.10	29.83	4.92	7.88
PB Ratio	6.41	27.93	8.48	6.70	2.83	3.25
P/TBV Ratio	6.41	27.93	8.48	33.34	4.68	5.02
EV/Sales Ratio	7.82	44.64	96.62	28.74	4.61	7.28
Debt / Equity Ratio	0.20	-	-	0.27	0.18	0.14
Net Debt / Equity Ratio	-0.76	-1.48	-1.05	-0.43	-0.13	-0.20
Net Debt / EBITDA Ratio	0.43	0.25	1.85	1.27	0.71	1.58
Net Debt / FCF Ratio	0.36	0.29	2.08	1.05	0.75	1.68
Asset Turnover	0.39	0.20	0.10	0.11	0.43	0.34
Inventory Turnover	-	-	-	-	0.31	0.24
Quick Ratio	1.98	2.73	12.00	2.13	2.24	3.58
Current Ratio	2.18	2.84	12.42	2.24	3.20	4.78
Return on Equity (ROE)	-147.09%	-254.33%	-126.09%	-26.80%	-20.43%	-15.37%
Return on Assets (ROA)	-60.21%	-136.74%	-42.14%	-12.71%	-9.63%	-7.33%
Return on Capital Employed (ROCE)	-179.20%	-599.50%	-56.90%	-34.50%	-18.20%	-12.70%
Earnings Yield	-27.96%	-21.07%	-8.84%	-23.84%	-7.70%	-4.64%
FCF Yield	-32.87%	-18.15%	-5.96%	-6.13%	-6.20%	-3.61%
Buyback Yield / Dilution	-14.98%	-31.44%	-15.51%	-1.30%	-0.36%	-6.66%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.